Patents by Inventor Kristian Berg
Kristian Berg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230314441Abstract: The present invention relates to compositions and methods for cancer therapy, including but not limited to, therapies that utilize cancer biomarkers. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies.Type: ApplicationFiled: October 14, 2022Publication date: October 5, 2023Inventors: Anette Weyergang, Maria Eb Berstad, Kristian Berg, Olav Engebraten
-
Publication number: 20230184777Abstract: The present invention relates to compositions and methods for cancer therapy, including but not limited to, therapies that utilize cancer biomarkers. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies.Type: ApplicationFiled: October 14, 2022Publication date: June 15, 2023Inventors: Anette Weyergang, Maria Eb Berstad, Kristian Berg, Olav Engebraten
-
Patent number: 11506668Abstract: The present invention relates to compositions and methods for cancer therapy, including but not limited to, therapies that utilize cancer biomarkers. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies.Type: GrantFiled: June 22, 2018Date of Patent: November 22, 2022Inventors: Olav Engebråten, Maria Eb Berstad, Kristian Berg, Anette Weyergang
-
Publication number: 20210121570Abstract: The invention provides mitochondria-targeted chemiluminescent agents and their use in methods of photodynamic therapy (PDT). In particular, the invention provides compounds of general formula (I), and their pharmaceutically acceptable salts: (I) in which A represents a chemiluminescent moiety; each L, which may be the same or different, is either a direct bond or a linker; each B, which may be the same or different, represents a mitotropic moiety; n is an integer from 1 to 3, preferably 1; and x is an integer from 1 to 3, preferably 1. Such compounds find particular use in the treatment of deeply-sited tumours, e.g. glioblastoma multiforme (GBM), when used in combination with a photosensitizer or photosensitizer precursor.Type: ApplicationFiled: June 21, 2018Publication date: April 29, 2021Inventors: Georgios C. VOUGIOUKALAKIS, Georgios ROTAS, Theodossis A. THEODOSSIOU, Kristian BERG, Ángel Miranda Alonso MIGUEL
-
Publication number: 20200182879Abstract: The present invention relates to compositions and methods for cancer therapy, including but not limited to, therapies that utilize cancer biomarkers. In particular, the present invention relates to compositions and methods for the prediction of a subject's response to cancer therapies.Type: ApplicationFiled: June 22, 2018Publication date: June 11, 2020Inventors: Olav ENGEBRÅTEN, Maria Eb BERSTAD, Kristian BERG, Anette WEYERGANG
-
Patent number: 9901636Abstract: The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitizing agent, and uses thereof in photochemical internalization (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.Type: GrantFiled: May 14, 2013Date of Patent: February 27, 2018Assignee: PCI BIOTECH ASInventors: Kristian Berg, Anders Hogset, Mar Masson, Vivek S. Gaware
-
Patent number: 9737594Abstract: The present invention provides a method of stimulating an immune response to an antigenic molecule, by contacting a cell with the antigenic molecule and with a photosensitizing agent, irradiating the cell, and thereby presenting the antigenic molecule, or part thereof, on the surface of said cell and stimulating an immune response.Type: GrantFiled: July 5, 2012Date of Patent: August 22, 2017Assignee: PCI Biotech ASInventors: Kristian Berg, Torunn E. Tjelle, Anders Hogset, Lina Prasmickaite
-
Patent number: 9241996Abstract: The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, and to the use of this method for enhancing the effects of kinase inhibitors or kinase inhibitor-based drugs in particular to achieve cell death, for example, in cancer treatment and other diseases or conditions in which kinase inhibitors, such as TKIs, have a beneficial effect.Type: GrantFiled: June 26, 2009Date of Patent: January 26, 2016Assignee: PCI BIOTECH ASInventors: Anders Høgset, Anette Weyergang, P{dot over (a)}l Kristian Selbo, Kristian Berg
-
Publication number: 20150202293Abstract: The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitising agent, and uses thereof in photochemical internalisation (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes.Type: ApplicationFiled: May 14, 2013Publication date: July 23, 2015Applicant: PCI BIOTECH ASInventors: Kristian Berg, Anders Hogset, Mar Masson, Vivek S. Gaware
-
Publication number: 20130330363Abstract: The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. Methods of vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.Type: ApplicationFiled: July 5, 2012Publication date: December 12, 2013Applicant: PCI Biotech ASInventors: Kristian Berg, Torunn E. Tjelle, Anders Hogset, Lina Prasmickaite
-
Patent number: 8216587Abstract: The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of an antigen-presenting cell, said method comprising introducing a molecule into the cell cytosol by photochemical internalisation, wherein said molecule, or a part thereof, is subsequently presented on the surface of said cell. Methods of vaccination comprising this method, together with compositions comprising said cells and uses involving said cells expressing antigenic molecules are also provided.Type: GrantFiled: March 10, 2000Date of Patent: July 10, 2012Assignee: PCI Biotech ASInventors: Kristian Berg, Torunn E. Tjelle, Anders H øgset, Lina Prasmickaite
-
Patent number: 8096419Abstract: The present invention provides photosensitizing agents obtained by reducing a single double bond in the porphyrin macrocycle of a sulphonated meso-tetraphenylporphyrin, preferably a disulphonated meso-tetraphenylporphyrin such as TPPS2a. The resulting sulphonated meso-tetraphenyl chlorins include compounds of formula I: (wherein X is —SO3H; n, p, q and r are each independently 0 or 1; and the sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, e.g. 2 or 4) isomers and isomer mixtures thereof. The compounds of the invention and their pharmaceutically acceptable salts find particular use as photosensitizing agents in the photochemical internalization of molecules and in photodynamic therapy.Type: GrantFiled: January 19, 2010Date of Patent: January 17, 2012Assignee: PCI Biotech ASInventors: Claude Rimington, Greta Rimington, legal representative, Kristian Berg, Diem Thuy Thi Tran, Pal Kristian Selbo
-
Publication number: 20110293575Abstract: The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, and to the use of this method for enhancing the effects of kinase inhibitors or kinase inhibitor-based drugs in particular to achieve cell death, for example, in cancer treatment and other diseases or conditions in which kinase inhibitors, such as TKIs, have a beneficial effect.Type: ApplicationFiled: June 26, 2009Publication date: December 1, 2011Applicant: PCI BIOTECH ASInventors: Anders Høgset, Anette Weyergang, Pål Kristian Selbo, Kristian Berg
-
Patent number: 8008077Abstract: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.Type: GrantFiled: May 9, 2007Date of Patent: August 30, 2011Assignee: PCI Biotech ASInventors: Kristian Berg, Lina Prasmickaite, Anders Hogset, Pal Kristian Selbo
-
Publication number: 20100121255Abstract: The present invention provides photosensitizing agents obtained by reducing a single double bond in the porphyrin macrocycle of a sulphonated meso-tetraphenylporphyrin, preferably a disulphonated meso-tetraphenylporphyrin such as TPPS2a. The resulting sulphonated meso-tetraphenyl chlorins include compounds of formula I: (wherein X is —SO3H; n, p, q and r are each independently 0 or 1; and the sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, e.g. 2 or 4) isomers and isomer mixtures thereof. The compounds of the invention and their pharmaceutically acceptable salts find particular use as photosensitizing agents in the photochemical internalization of molecules and in photodynamic therapy.Type: ApplicationFiled: January 19, 2010Publication date: May 13, 2010Applicant: THE NORWEGIAN RADIUM HOSPITAL RESEARCH FOUNDATIONInventors: Claude Rimington, Greta Rimington, Kristian Berg, Diem Thuy Thi Tran, Pal Kristian Selbo
-
Patent number: 7662807Abstract: The present invention provides photosensitizing agents obtained by reducing a single double bond in the porphyrin macrocycle of a sulphonated meso-tetraphenylporphyrin, preferably a disulphonated meso-tetraphenylporphyrin such as TPPS2a. The resulting sulphonated meso-tetraphenyl chlorins include compounds of formula (I) (wherein X is —SO3H; n, p, q and r are each independently 0 or 1; and the sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, e.g. 2 or 4) isomers and isomer mixtures thereof. The compounds of the invention and their pharmaceutically acceptable salts find particular use as photosensitizing agents in the photochemical internalization of molecules and in photodynamic therapy.Type: GrantFiled: August 30, 2002Date of Patent: February 16, 2010Assignee: The Norwegian Radium Hospital Research FoundationInventors: Claude Rimington, Greta Rimington, legal representative, Kristian Berg, Diem Thuy Thi Tran, Pal Kristian Selbo
-
Patent number: 7521239Abstract: A method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitizing agent, the cell is irradiated with light of a wavelength effective to activate the photosensitizing agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.Type: GrantFiled: November 29, 2001Date of Patent: April 21, 2009Assignee: PCI Biotech ASInventors: Anders Høgset, Kristian Berg, Gunhild Mari Mælandsmo, Birgit Øvstebø Engesæter, Lina Prasmickaite
-
Publication number: 20070274953Abstract: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.Type: ApplicationFiled: May 9, 2007Publication date: November 29, 2007Applicant: PCI BIOTECH ASInventors: Kristian BERG, Lina PRASMICKAITE, Anders HOGSET, Pal SELBO
-
Patent number: 7223600Abstract: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosentistising agent, the cell is irradiated with light of a wavelength effective to activate the photosentisitising agent and, substantially at the same time or after the irradiation, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination.Type: GrantFiled: November 29, 2001Date of Patent: May 29, 2007Assignee: The Norwegian Radium Hospital Research FoundationInventors: Kristian Berg, Lina Prasmickaite, Anders Høgset, Pål Kristian Selbo
-
Publication number: 20060052433Abstract: The present invention provides photosensitizing agents obtained by reducing a single double bond in the porphyrin macrocycle of a sulphonated meso-tetraphenylporphyrin, preferably a disulphonated meso-tetraphenylporphyrin such as TPPS2a. The resulting sulphonated meso-tetraphenyl chlorins include compounds of formula (I) (wherein X is —SO3H; n, p, q and r are each independently 0 or 1; and the sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, e.g. 2 or 4) isomers and isomer mixtures thereof. The compounds of the invention and their pharmaceutically acceptable salts find particular use as photosensitizing agents in the photochemical internalization of molecules and in photodynamic therapy.Type: ApplicationFiled: August 30, 2002Publication date: March 9, 2006Inventors: Kristian Berg, Diem Thuy Tran, Pal Selbo